As someone who has worked in pharma, this article is pretty damn ignorant. There’s a ton of funding for pharmacokinetics work. For liver and the gut, it is wide

As someone who has worked in pharma, this article is pretty damn ignorant. There’s a ton of funding for pharmacokinetics work. For liver and the gut, it is widely agreed that 2-D tissue culture is completely non-predictive, so the last couple of decades have been building 3-D tissue culture and nowadays, companies commercially purchase organs on a chip for both and even multi-organ systems[0]. Plenty of companies have internal teams that have built similar technology and they all have teams working hard trying to build computational models on the generated data. But small changes in molecules have huge ADMET impacts and these organs are just a subset of the organs that can impact pharmacokinetics. Plus, toxicology can tank a drug by impacts on nearly any organ, so whole animal models always still win. The entire article just yells ignorance of what drug companies work on and what they’re investing in. [0] https://cn-bio.com/models/ https://cn-bio.com/models/